Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchUDCAUDCA (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
UDCA for COVID-19
12 studies from 170 scientists
36,975 patients in 6 countries
Statistically significant lower risk for cases.
6 studies from 6 independent teams in 3 countries show statistically significant improvements.
COVID-19 UDCA studies. Feb 2024. c19early.org
0 0.5 1 1.5+ All studies 15% Mortality 4% Hospitalization 17% Cases 13% Prophylaxis 15% Favorsursodeoxycholic acid Favorscontrol
Feb 20
Covid Analysis Ursodeoxycholic acid for COVID-19: real-time meta analysis of 12 studies
Statistically significant lower risk is seen for cases. 6 studies from 6 independent teams in 3 countries show statistically significant improvements. Meta analysis using the most serious outcome reported shows 15% [2‑26%] lowe..
Feb 13
Huang et al., Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2024.02.011 Bile acids and coronavirus disease 2019
Review of the relationship between bile acids and COVID-19. Authors discuss emerging basic and clinical evidence linking bile acids to COVID-19 infection and potential mechanisms. Functionally, studies indicate that certain bile acids lik..
Jan 19
Corpechot et al., Journal of Medical Virology, doi:10.1002/jmv.29418 Exploring the impact of ursodeoxycholic acid therapy on COVID‐19 in a real‐word setting
19% lower ICU admission (p=1) and 40% lower hospitalization (p=0.17). Retrospective cohort study of 10,147 chronic liver disease patients in France, with 1,322 exposed to ursodeoxycholic acid (UDCA), showing lower risk of hospitalization for COVID-19 with UDCA exposure, without statistical significance (adj..
Dec 13
2023
Costello et al., medRxiv, doi:10.1101/2023.12.11.23299191 Ursodeoxycholic acid and severe COVID-19 outcomes in people with liver disease: a cohort study using the OpenSAFELY platform
24% lower mortality (p=0.13), 19% lower hospitalization (p=0.02), and 21% lower combined mortality/hospitalization (p=0.005). OpenSAFELY retrospective 11,320 primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) patients showing lower risk of COVID-19 hospitalization or death with ursodeoxycholic acid (UDCA) treatment.
Dec 9
2023
Fiorucci et al., Biochemical Pharmacology, doi:10.1016/j.bcp.2023.115983 Bile acids and bile acid activated receptors in the treatment of Covid-19
Review of the potential role of bile acids and bile acid activated receptors in modulating SARS-CoV-2 infectivity and inflammation in COVID-19. Authors discuss mechanisms by which bile acids like ursodeoxycholic acid (UDCA), chenodeoxycho..
Nov 28
2023
Gao et al., Blood, doi:10.1182/blood-2023-182862 Effect of Ursodeoxycholic Acid for Sars-Cov-2 Prevention in Hematological Malignancies: An Observational Real-World Study
12% fewer cases (p=0.03). Retrospective 393 hospitalized patients with hematologic disorders in China, showing lower risk of COVID-19 with UDCA use.
Nov 16
2023
Ming et al., Microbiology and Infectious Diseases The American Medical Journal, doi:10.33590/microbiolinfectdisamj/10304488 A Retrospective Study in Patients With Varying Prescription Coverage With Ursodeoxycholic Acid and Association With Incidence of COVID-19 Diagnosis in Primary Care
13% fewer cases (p=0.03). Retrospective 8,964 primary care patients prescribed ursodeoxycholic acid (UDCA) in the UK. Higher categorized UDCA adherence (≥80%) was associated with lower COVID-19 incidence (OR 0.86), whereas adherence as a continuous variable was no..
Sep 21
2023
Marrone et al., Liver International, doi:10.1111/liv.15736 Ursodeoxycholic acid does not affect the clinical outcome of SARS‐CoV‐2 infection: A retrospective study of propensity score‐matched cohorts
7% higher mortality (p=0.77). PSM retrospective 629 hospitalized COVID-19 patients showing no significant difference in survival between 108 patients taking UDCA prior to infection compared to 521 matched controls not taking the drug. The lack of observed benefit in t..
Aug 22
2023
Ojeda‐Fernández et al., Journal of Internal Medicine, doi:10.1111/joim.13711 UDCA treatment against COVID‐19: Do we have enough clinical evidence for drug repurposing?
7% higher mortality (p=0.67), 4% lower ICU admission (p=0.96), 6% higher hospitalization (p=0.66), and 3% fewer cases (p=0.77). Retrospective cohort study of 9,617 patients with liver disease in Italy, divided into UDCA users and non-users. UDCA exposure was not associated with reduced SARS-CoV-2 infection or improved COVID-19 outcomes including death, hospitaliza..
Aug 14
2023
Colapietro et al., Viruses, doi:10.3390/v15081738 Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients
no change in mortality (p=0.24). Retrospective 3,847 COVID-19 patients hospitalized in Italy, including 57 treated with UDCA. UDCA treatment was not associated with reduced mortality, however treatment was associated with a lower rate of CPAP use. It's not clear how the ..
Jul 27
2023
Okushin et al., Journal of Internal Medicine, doi:10.1111/joim.13704 Ursodeoxycholic acid for coronavirus disease 2019 prevention
17% fewer symptomatic cases (p=0.81) and no change in cases (p=1). Retrospective 94 outpatients attending a university hospital gastroenterology clinic in Japan showing no significant difference in SARS-CoV-2 infection rates between ursodeoxycholic acid (UDCA)-treated patients and control groups without ..
Jun 29
2023
Liu et al., Liver International, doi:10.1111/liv.15660 Ursodeoxycholic acid administration did not reduce susceptibility to SARS‐CoV‐2 infection in children
2% more cases (p=0.88). Retrospective 280 Chinese families with children previously seen in a liver clinic assessing whether ursodeoxycholic acid (UDCA) reduced SARS-CoV-2 infection risk. Among infected families, the study found no significant difference in conf..
May 4
2023
Yu et al., medRxiv, doi:10.1101/2023.05.02.23289410 UDCA May Promote COVID-19 Recovery: A Cohort Study with AI-Aided Analysis
38% improved recovery (p=0.05). Retrospective 115 COVID-19 patients hospitalized during an Omicron outbreak in China, of which 65 received ursodeoxycholic acid (UDCA) treatment and 50 received standard care. It found that UDCA was associated with faster body temperature..
May 3
2023
Li et al., Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2023.1178590 Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease
80% lower severe cases (p=0.22), 80% fewer moderate/severe cases (p<0.0001), and 11% fewer cases (p=0.05). Retrospective propensity score matched cohort study of 225 chronic liver disease patients on UDCA therapy matched to 225 controls without UDCA in China. UDCA use was associated with lower COVID-19 infection rate (85% vs 94%), lower maximu..
Apr 5
2023
John et al., Journal of Internal Medicine, doi:10.1111/joim.13630 Ursodeoxycholic acid is associated with a reduction in SARS‐CoV‐2 infection and reduced severity of COVID‐19 in patients with cirrhosis
46% fewer cases (p<0.0001). Retrospective 3,214 veterans with cirrhosis comparing 1,607 participants taking ursodeoxycholic acid (UDCA) to 1,607 propensity score matched controls not taking UDCA. UDCA use was associated with significantly lower odds of SARS-CoV-2 in..
Dec 5
2022
Brevini et al., Nature, doi:10.1038/s41586-022-05594-0 FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
94% lower mortality (p=0.13), 75% lower ICU admission (p=0.21), and 40% lower hospitalization (p=0.03). Retrospective study from two registries of 1,096 COVID-19 patients with chronic liver disease, including 31 treated with ursodeoxycholic acid (UDCA). Propensity score matching was used to compare outcomes between UDCA-treated and untreate..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit